The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.
July 21st 2025
No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 inhibitor (SGLT2i) users with type 2 diabetes, study finds.
Understand how recent advances in GLP-1 receptor agonists and other therapies are transforming the treatment of type 2 diabetes and obesity through a shift of reactive to proactive care that addresses root causes of cardiometabolic disease.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Dr Scott Breidbart Explains the Concerns With Paying for Adherence
Millennials Show Improved Health, Well-Being Compared With Older Generations